Reports
Global Hospital-Acquired Infection Treatment Market Share, Size, Growth: By Products and Services: Sterilization, Cleaning and Disinfection Products, Protective Barriers, Endoscope Reprocessing Products; By Infection Type: Hospital-acquired Pneumonia, Others; By Application; By End User; Regional Analysis; Supplier Landscape; 2023-2031
Global Hospital-Acquired Infection Treatment Market Outlook
The hospital-acquired infection treatment market size was estimated to be worth USD 15.31 billion in 2022. The market is expected to rise at a growth rate of 4.2% in the forecast period of 2023-2031 to attain a market size of nearly USD 20.07 billion by 2031. Novel therapy launches and approvals are expected to fuel the market growth during the forecast period.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Hospital-Acquired Infection: Type, Causes, Diagnosis, and Treatment
Hospital-acquired infection are infections that are acquired by the hospital or any other healthcare facility or from any healthcare professional, including doctors and nurses, among others, during the course of the treatment. The hospital-acquired infection are also referred to as healthcare-associated infections and nosocomial infections.
There are different types of healthcare-associated infections depending on the mode of entry of the causative pathogen and the type of the pathogen. According to the Centers for Disease Control and Prevention, nearly 1.7 million healthcare-associated infections were reported in the United States.
There are several modes of transmission attributing to the widespread of hospital-acquired infection, such as contact transmission, droplet transmission, airborne transmission, common vehicle transmission, and vector-borne transmission.
Nosocomial infections can be prevented by following several preventative steps and measures including sanitation, sterilisation, isolation, and frequent sanitation habits. The treatment for these types of infections is solely based on the eradication of the causative agents, responsible for causing the disease.
There are different antibiotics approved for eradicating or slowing the growth of the gram-positive strains of Staphylococcus aureus and gram-negative strains of Acinetobacter baumannii. Several other novel therapeutic medications are under clinical development for providing better therapeutic and diagnostic care.
According to the hospital-acquired infection treatment market research report, the market can be categorised into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Product and Services
- Sterilization
- Sterilization Products
- Heat Sterilization Equipment
- Low-Temperature Sterilization Equipment
- Radiation Sterilization Equipment
- Other Sterilization Equipment
- Contract Sterilization Services
- Sterilization Consumables and Accessories
- Sterilization Products
- Cleaning and Disinfection Products
- Disinfectants
- Disinfectors Equipment
- Others
- Protective Barriers
- Endoscope Reprocessing Products
Market Breakup by Infection Type
- Hospital-acquired Pneumonia
- Bloodstream Infections
- Surgical Site Infections
- Gastrointestinal Infections
- Urinary Tract Infections (UTIs)
- Others
Market Breakup by Application
- Drug-Resistance Testing
- Disease Testing
- Others
Market Breakup by End User
- Hospitals and ICUs
- Ambulatory Surgical and Diagnostic Centres
- Nursing Homes and Maternity Centres
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Scenario
The growth of the hospital-acquired infection treatment market is primarily driven by the rising incidence and prevalence of healthcare-associated infections. This is further stimulated by the growing cases of chronic disorders and surgeries, which require prolonged hospital stays and thus will increase the risk of acquiring nosocomial infections. Additionally, the technological advancements in the devices implemented for infection control are also expected to bolster the market growth during the forecast period.
The hospital-acquired infection treatment market is augmented by the higher rate of surgical site infections, which is anticipated to increase the demand for the products and devices to manage hospital-acquired infection, and henceforth propel the market growth. According to the Centers for Disease Control and Prevention, nearly 20,000 surgical site infections were reported in the United States, thus accounting for significant market growth.
With extensive research and innovation, there is the discovery of novel therapeutic products by the key players and the major pharmaceutical companies. For example, Esco discovered a new sterilization device, incorporating a Cell Culture CO2 Incubator with High Heat Sterilization (CCL-HHS). The discovery of these devices will aid the eradication of the microorganisms contaminating the marketplace. Such product launches and approvals are expected to boost the market expansion in the forthcoming period.
Among the products segment, the disinfectants segment is anticipated to dominate the hospital-acquired infection treatment market owing to the increasing prevalence of chronic disorders, hospital-acquired infection, rising awareness, and the growing number of surgical interventions. Several reports suggested that nearly half of nosocomial infections occur in the intensive care units. The application of surface disinfectants aid in the prevention of these infections and will boost the market growth.
North America Accounts for the Largest Share
North America is anticipated to account for the largest share of the hospital-acquired infection treatment market due to the growth in hospital stays with the increase in the number of chronic diseases and surgeries. This can be attributed to the rising number of hospital admissions, that too for an extended period. Further, this will also increase the chances of hospital-acquired infection and will bolster the market development.
Therapeutic Landscape
The hospital-acquired infection are generally treated with the help of medications and other home remedies. The diagnosis of the infection is performed using the help of blood tests, X-rays, and other diagnostic tests based on the symptoms.
Antibiotics are the most prescribed medications used for the treatment of nosocomial infections. The antibiotics act against the bacteria responsible for causing the infections by killing them or slowing their growth.
The two bacteria species that are likely to infect patients are Gram-positive strains of Staphylococcus aureus and Gram-negative strains of Acinetobacter baumannii. The frequent hospital-acquired infection are of the surgical site, urinary tract, and several types of pneumonia. An alternative treatment strategy used for the management of these infections is irradiation incorporating ultraviolet C.
In case the infection is caused by any foreign device such as a catheter, the doctor may remove it for the appropriate medical period. Home remedies such as the administration of a balanced diet, high fluid intake, and proper rest are the additional treatment measures that will assist in faster and better recovery.
Clinical Trials Landscape
With the increasing prevalence of chronic disorders, the risk of hospital-acquired infection also increases. For better diagnosis and treatment, clinical researchers and scientists are working on discovering novel therapeutic interventions that will aid in the management of non-cosmical infections.
Vir Biotechnology, a key market player, is evaluating the potential of its new therapies, VIR-3434 and VIR-2218, that could be considered as a functional cure for chronic hepatitis virus infection. This type of infection is categorised as healthcare-associated, and if successfully passed, it will help in bolstering the growth of the hospital-acquired infection treatment market.
Ascentage Pharma, another major pharmaceutical company, is performing clinical trials for the novel drug, which is anticipated to act by inhibiting the apoptosis protein antagonist in Chinese patients suffering from chronic hepatitis virus, which can be acquired from hospitals and other medical centres.
With time, the bacterial strains develop microbial resistance against the available antibiotics, thus the scientists are working on developing novel treatment options for managing resistant pneumonia. The newer treatment methods and faster approvals by the regulatory authorities are expected to boost the hospital-acquired infection treatment market growth during the forecast period.
Competitive Landscape
The report gives an in-depth analysis of the key players involved in the hospital-acquired infection treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- 3M
- Belimed AG
- Ecolab Inc.
- Fortive
- Getinge AB
- Bayer AG
- Danaher
- Novartis AG
- Merck & Co., Inc.
- Abbott
- Pfizer Inc.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Products and Services |
|
| Breakup by Infection Type |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Hospital-Acquired Infection Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Hospital-Acquired Infection Treatment Market
8.1 Global Hospital-Acquired Infection Treatment Market Overview
8.2 Global Hospital-Acquired Infection Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Hospital-Acquired Infection Treatment Market Historical Value (2016-2022)
8.2.1.2 Global Hospital-Acquired Infection Treatment Market Forecast Value (2023-2031)
8.2.2 Global Hospital-Acquired Infection Treatment Market by Products and Services
8.2.2.1 Market Overview
8.2.2.1.1 Sterilization
8.2.2.1.1.1 Sterilization Products
8.2.2.1.1.1.1 Heat Sterilization Equipment
8.2.2.1.1.1.2 Low-Temperature Sterilization Equipment
8.2.2.1.1.1.3 Radiation Sterilization Equipment
8.2.2.1.1.1.4 Other Sterilization Equipment
8.2.2.1.1.2 Contract Sterilization Services
8.2.2.1.1.3 Sterilization Consumables and Accessories
8.2.2.1.2 Cleaning and Disinfection Products
8.2.2.1.2.1 Disinfectants
8.2.2.1.2.2 Disinfectors Equipment
8.2.2.1.2.3 Others
8.2.2.1.3 Protective Barriers
8.2.2.1.4 Endoscope Reprocessing Products
8.2.3 Global Hospital-Acquired Infection Treatment Market by Infection Type
8.2.3.1 Market Overview
8.2.3.1.1 Hospital-acquired Pneumonia
8.2.3.1.2 Bloodstream Infections
8.2.3.1.3 Surgical Site Infections
8.2.3.1.4 Gastrointestinal Infections
8.2.3.1.5 Urinary Tract Infections (UTIs)
8.2.3.1.6 Others
8.2.4 Global Hospital-Acquired Infection Treatment Market by Application
8.2.4.1 Market Overview
8.2.4.1.1 Drug-Resistance Testing
8.2.4.1.2 Disease Testing
8.2.4.1.3 Others
8.2.5 Global Hospital-Acquired Infection Treatment Market by End User
8.2.5.1 Market Overview
8.2.5.1.1 Hospitals and ICUs
8.2.5.1.2 Ambulatory Surgical and Diagnostic Centres
8.2.5.1.3 Nursing Homes and Maternity Centres
8.2.6 Global Hospital-Acquired Infection Treatment Market by Region
8.2.6.1 Market Overview
8.2.6.1.1 North America
8.2.6.1.2 Europe
8.2.6.1.3 Asia Pacific
8.2.6.1.4 Middle East and Africa
8.2.6.1.5 Latin America
9 North America Hospital-Acquired Infection Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Hospital-Acquired Infection Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific Hospital-Acquired Infection Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America Hospital-Acquired Infection Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa Hospital-Acquired Infection Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Global Hospital-Acquired Infection Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 3M
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Belimed AG
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Ecolab Inc.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Fortive
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Getinge AB
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Bayer AG
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Danaher
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Novartis AG
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Merck & Co., Inc.
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Abbott
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Pfizer Inc.
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
16 Hospital-Acquired Infection Treatment Market- Drug Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customizable as per client requirements.
Key Questions Answered in the Report
The market size is likely to reach a value of USD 15.31 billion in 2022.
The market is likely to grow at a CAGR of 4.2% during the forecast period of 2023-2031 to attain a value of USD 20.07 billion by 2031.
How is the hospital-acquired infection treatment market segmented based on the product and services?
Based on the product and services, the market is segmented into sterilisation, cleaning and disinfection products, protective barriers, and endoscope reprocessing products.
Based on the infection type, the market is categorised into hospital-acquired Pneumonia, bloodstream infections, surgical site infections, gastrointestinal infections, and urinary tract infections, among others.
Based on the application, the market is segmented into drug-resistance testing and disease testing, among others.
Based on the end user, the market is categorised into hospitals and ICUs, ambulatory surgical and diagnostic centres, nursing homes and maternity centres.
The different regions in the market are North America, Europe, Asia Pacific, Latin America and the Middle East and Africa.
The key companies involved in the market are 3M, Belimed AG, Ecolab Inc., Fortive, Getinge AB, Bayer AG, Danaher, Novartis AG, Merck & Co., Inc., Abbott, and Pfizer Inc., among others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$3499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER